We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Aditxt Inc (ADTX) USD0.001

Sell:$1.98 Buy:$2.15 Change: $0.02 (0.99%)
Market closed |  Prices as at close on 28 May 2024 | Switch to live prices |
Change: $0.02 (0.99%)
Market closed |  Prices as at close on 28 May 2024 | Switch to live prices |
Change: $0.02 (0.99%)
Market closed |  Prices as at close on 28 May 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Aditxt, Inc. is a biotech company focused on discovering, developing, and deploying health innovations. It develops and commercializes technologies with a focus on monitoring and modulating the immune system. Its portfolio includes Adimune, Inc., developing a new class of therapeutics designed to retrain the immune system to address organ rejection, autoimmunity, and allergies; Adivir, Inc., focused on identifying, developing, and commercializing new ways to treat infectious diseases, and Pearsanta, Inc., offering personalized lab testing, backed by CLIA-certified and CAP-accredited monitoring center. Adimune, Inc's immune modulation product candidate, ADI-100, is based on the Apoptotic DNA Immunotherapy platform technology, utilizes a novel approach that mimics the way bodies naturally induce tolerance to own tissues. It also offers electroencephalography (EEG) brain monitoring technologies and devices, including NeuroCap and NeuroEEG for telehealth and tele-neurology applications.

Contact details

737 N. Fifth Street, Suite 200
United States
+1 (909) 4880844

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$3.38 million
Shares in issue:
1.67 million
United States
US dollar

Key personnel

  • Amro Albanna
    Chairman of the Board, Chief Executive Officer
  • Thomas Farley
    Chief Financial Officer
  • Rowena Albanna
    Chief Operating Officer
  • Shahrokh Shabahang
    Chief Innovation Officer, Director
  • Corinne Pankovcin
    Chief Commercialization Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.